<DOC>
	<DOCNO>NCT02661659</DOCNO>
	<brief_summary>A phase Ib study investigate safety , immunogenicity optimal administration frequency S-588210 5-peptide vaccine MPM patient without progression pemetrexed-based chemotherapy conduct . Additionally , identify accurate predictive biomarkers response S-588210 , T-cell-receptor-sequencing ( TCR ) pre- post-vaccination perform blood sample patient treat vaccine . Immunohistochemical analysis vaccine oncoantigens also correlate induction antigen-specific T-cell response . Finally , explore infiltration tumor T-cells potential presence immunosuppressive tumor microenvironment , immunohistochemistry immune checkpoint ( include PDL1/PD1 , CTLA4 ) immune suppressive cell subset ( T-regs , macrophage ) perform .</brief_summary>
	<brief_title>A Phase Ib Trial Maintenance Multipeptide Vaccine ( S-588210 ) Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy</brief_title>
	<detailed_description>Primary Objective : To evaluate rate peptide-specific CTL induction S-588210 within first 8 month HLA-A*02:01-positive patient MPM progress first-line pemetrexed-based chemotherapy treat weekly every week vaccination schedule . Secondary Objectives : 1 . To evaluate safety S-588210 HLA-A*02:01-positive patient MPM treat S-588210 2 . To determine disease control rate ( DCR ) HLA-A*02:01-positive patient MPM treat S-588210 3 . To determine progression-free-survival ( PFS ) HLA-A*02:01-positive patient MPM progress first-line pemetrexed-based chemotherapy treat S-588210 4 . To evaluate peptide-specific CTL response S-588210 time 8 month HLA-A*02:01-positive patient MPM progress first-line pemetrexed-based chemotherapy</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients unresectable MPM complete 46 cycle standard firstline pemetrexedbased chemotherapy least 1 month progress Age &gt; 18 Able provide inform consent study HLAA*02:01 positive ECOG PS=01 enrollment Measurable indicator lesion modify RECIST criterion Adequate bone marrow ( ANC &gt; 1000cells/ml , PLT &gt; 50,000/ml , Hg &gt; 8gr/dL ) , renal ( Cr &gt; 2.5xUNL ) liver function ( AST , ALT &lt; 3x UNL , total bilirubin &lt; 2x UNL , ALP &lt; 3x UNL ) Archival tumor tissue available IHC ( 1 paraffinembedded block ) Epithelioid biphasic histology Chemotherapy investigational antineoplastic drug within 1 month plan initiation vaccine therapy Patients receive DEPDC1 , MPHOSPH1 , URLC10 , CDCA1 , KOC1 peptide vaccine Active treatment corticosteroid immunosuppressive agent Patients expect require follow therapy enrollment completion discontinuation study treatment : 1. immunosuppressive drug , include corticosteroid , methotrexate , mercaptopurine , azathioprine , cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil , ATG ( antithymoglobulin ) , IL2receptor antibody ( basiliximab , daclizumab ) , TNFa antibody ( infliximab , etanercept , adalimumab ) 2. radiotherapy target disease 3. surgical therapy target disease History bone marrow transplantation Active infection Human immunodeficiency virus infection History active systemic autoimmune disorder immunodeficiency syndromes History severe ( CTCAE v.4.03 grade 3 high ) allergic reaction drug , vaccination , biological preparation . Pregnancy Patients intend practice effective contraception Severe illness require hospitalization Lymphocytes &lt; 15 % total WBCs baseline Sarcomatoid histology Severe ( CTCAE v.4.03 grade 3 high ) concurrent hepatic impairment , renal impairment , heart disease , hematological disease , respiratory disease , metabolic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>mesothelioma</keyword>
	<keyword>multipeptide vaccine</keyword>
	<keyword>S-588210</keyword>
</DOC>